<unk>  was first used in 1961 to treat peptic ulcers. Since 1975, intravenous<unk>  has been used before surgery to reduce salivary, tracheobronchial, and pharyngeal secretions. It is also used in conjunction with neostigmine, a neuromuscular blocking reversal agent, to prevent neostigmine's muscarinic effects such as bradycardia. It can be administered to raise the heart rate in bradycardia, which often will also increase the blood pressure. It is also used to reduce excessive saliva (sialorrhea), and Ménière's disease. It has been used topically and orally to treat hyperhidrosis, in particular, gustatory hyperhidrosis. In inhalable form it is used to treat chronic obstructive pulmonary disease (COPD). Doses for inhalation are much lower than oral ones, so that swallowing a dose will not have an effect. In end-of-life care, this medication will often be administered to patients that become encumbered by their bronchial secretions and are no longer able to clear their own airway through insufficient coughing reflex.
Glycopyrronium bromide
Hyoscine butylbromide
Bromethalin
Bethanechol
Clofoctol
Dicycloverine
Cyclobenzaprine
Tesofensine